Handbook of Clinical medicine

Empirical treatment of pneumonia (check local policy) 167 Clinical Antibiotic (further dosage Organisms setting details: pp386–7) Community-acquired Mild not Streptococcus pneumoniae Oral amoxicillin 500mg–1g/8h or clarithro- previously  Haemophilus infl uenzae mycin 500mg/12h or doxyc ycline 200mg CURB 0–1 loading then 100mg/day (initially 5-day course) Moderate Streptococcus pneumoniae Oral amoxicillin 500mg–1g/8h + CURB 2 Haemophilus infl uenzae clarithromycin 500mg/12h or doxyc ycline 200mg loading then 100mg/12h Mycoplasma pneumoniae If IV required: amoxicillin 500mg/8h + clarithromycin 500mg/12h (7-day course) Severe As above Co-amoxiclav 1 . 2g/8h IV or cephalosporin IV CURB >3 (eg cefuroxime 1 . 5g/8h IV) AND clarithromy- cin 500mg/12h IV (7 days) Add fl ucloxacillin ± rifampicin if Staph sus- pected; vancomycin (or teicoplanin) if MRSA suspected. Treat for 10d (14–21d if Staph, Legionella, or Gram Ωve enteric bacteria suspected) Panton-Valentine Seek urgent help. Consider adding IV Leukocidin-producing linezolid, clindamycin, and rifampicin Staph. aureus (PVL-SA) Atypical Legionella pneumophilia Fluoroquinolone combined with clarithro- mycin, or rifampicin, if severe. See p168 Chlamydophila species Tetracycline Pneumocystis jirovecii High-dose co-trimoxazole (pp400–1) Hospital-acquired Gram-negative bacilli Aminoglycoside IV + antipseudomonal Pseudomonas penicillin IV or 3rd-generation cephalosporin Anaerobes IV (p387) Aspiration Streptococcus pneumoniae Cephalosporin IV + metronidazole IV Anaerobes Neutropenic patients Gram-positive cocci Aminoglycoside IV
